Poor
Needs Revision
Patient Risk:
High
Summary
Mechanism and a subset of safety-related claims are partially supported by the provided label sections, but most dosing and multiple counseling/side-effect statements are not supported by the supplied prescribing information excerpts, creating substantial alignment gaps.
Category Scores
Accurate Statements
Dorzolamide is a carbonic anhydrase inhibitor.
12.1 Mechanism of Action (inhibitor of human carbonic anhydrase II).
Unsupported Statements
Dorzolamide eye drops are used to lower intraocular pressure in conditions such as glaucoma and ocular hypertension.
No indication/supporting labeling text was provided in the prompt excerpts (absent from the label citations supplied).
Dorzolamide eye drops are dosed as one drop in the affected eye(s) up to three times daily in common regimens.
No dosage/administration instructions were provided in the prompt excerpts (absent from the label citations supplied).
The exact dorzolamide dosing schedule can vary based on diagnosis and whether other pressure-lowering eye drops are being used.
No dosage/administration variability language was provided in the prompt excerpts (absent from the label citations supplied).
Local side effects after applying dorzolamide may include mild burning, stinging, or irritation.
No adverse reaction/counseling symptom list was provided in the prompt excerpts (absent from the label citations supplied).
Local side effects after applying dorzolamide may include temporarily blurred vision.
No adverse reaction/counseling symptom list was provided in the prompt excerpts (absent from the label citations supplied).
Dorzolamide may cause a bitter taste in the mouth due to drainage through the tear duct.
No label excerpt provided supports this specific adverse effect mechanism (absent from the label citations supplied).
More serious effects of dorzolamide can occur and should be discussed with a clinician, especially if symptoms persist or worsen.
No label excerpt provided the specific counseling threshold/timing for this statement (absent from the label citations supplied).
Dorzolamide can be used alongside other classes of glaucoma medications (for example, prostaglandin analogs or beta blockers) for better pressure control.
No combination/adjunct-use guidance was provided in the prompt excerpts (absent from the label citations supplied).
Seek prompt medical advice for signs of an allergic reaction after using dorzolamide, such as swelling, hives, or trouble breathing.
While sulfonamide hypersensitivity guidance exists, the prompt excerpts do not provide the specific “seek prompt medical advice” symptom examples (absent from the label citations supplied).
Seek prompt medical advice for severe eye pain, marked redness, or worsening vision after using dorzolamide.
No label excerpt provided this specific urgency/symptom set (absent from the label citations supplied).
Contradictions
Low
AI Statement
Dorzolamide eye drops are dosed as one drop in the affected eye(s) up to three times daily in common regimens.
Label Reference
Not verifiable/contradiction cannot be determined from provided excerpts (dosage section not provided).
Important Omissions
FDA label dosing/administration instructions (e.g., exact dosing frequency, strength-specific directions, and administration timing).
Importance:
High
FDA label adverse reaction statements or frequency information for local ocular effects and systemic effects.
Importance:
High
FDA label indication language/approved conditions and any eligibility limitations tied to the indication.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
High
Multiple dosing and symptom-counseling claims are not supported by the provided label excerpts, and the prompt does not include the label sections required to verify those safety-critical details.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Needs Revision
Primary Issue
Unsubstantiated dosing and multiple adverse-effect/counseling statements not supported by the supplied label excerpts.
Suggested Improvement
Replace unverifiable dosing, local side effects, and “seek prompt medical advice” symptom guidance with text that is directly supported by the FDA label sections for dosing/administration and patient counseling (not included in the prompt excerpts).